November 16, 2016
In 2013, Diazon Pharmaceuticals teamed up with The Laboratory for Therapeutic Development (LTD) to identify the mechanism of action of a potential new anticancer agent called DZ-2384. Members of the LTD, Dr. Joseph Tcherkezian, Cynthia Bernier, Dr. Yannève Rolland and Claude Godbout carried out functional genomic screens to identify the anti-mitotic mechanism. They then went on to characterize its unique effects on microtubule dynamics compared with other anti-mitotics as well as to determine the activity of the compound in several mouse tumor models. The study, published in Science Translational Medicine, was led by Drs. Anne Roulston and Gordon Shore along with Dr. Gary Brouhard Dept of Biology, and includes as collaborators GCRC members Drs. Peter Siegel and George Zogopoulos as well as several international labs.